Tagged with Funding

China I-Mab Biopharma CFO Jielun Zhu recaps the exciting milestones for the company over the past year since our last interview in May 2019, including most notably their NASDAQ IPO in January 2020, as well as shares some insights on the NASDAQ IPO experience.   Before the IPO, we might have…

China Michael Zhang, chairman of Peijia Medical, shares Peijia Medical’s mission to become a two-platform medical device company as well as the partner of choice for physicians in China and globally. Peijia Medical’s recent achievements include a Series C round, of over USD 100 million, and the successful completion of clinical…

Opinion Michael Jewell, partner and head of healthcare & life sciences at Cavendish Corporate Finance looks back at the key trends across pharma industry funding in 2019 and gives his perspective on how 2020 will look.   As we approach the end of 2019, it’s a good time to look back…

Japan Yuzo Toda, chairman of the Forum for Innovative Regenerative Medicine (FIRM) in Japan, discusses how the organization acts as a translational bridge between academia and industry, how the paradigm of regenerative medicine differs from that of traditional pharmaceuticals, and why Japan has taken the lead in this exciting new field.…

Japan Makoto Suematsu, president of the Japan Agency for Medical Research and Development (AMED), discusses AMED’s successful unification of Japan’s previously disparate systems for medical research funding; the strategic significance of the country’s strong footprint in regenerative medicine and rare diseases; and the organization’s internationalization strategy, propelled by the push to…

Austria Michael Stampfer, managing director of the Vienna Science and Technology Fund (WWTF), the only private, non-profit organization in Vienna dedicated to funding scientific research, discusses the challenges scientific research faces in Austria and how the organization helps bridge the gap between academia and industry. Furthermore, he illustrates the steps taken…

Switzerland Philippe Held, founder of the innovative Swiss medtech Dermosafe, discusses the origins behind the company’s game-changing digitalized solutions for detecting skin cancer at an early stage, how the rollout of the technology is progressing, and the importance of patient and physician education. You founded DermoSafe around five years ago with…

Taiwan Wu Tsung-Tsong, Minister Without Portfolio of the Republic of China (Taiwan) supervises and coordinates Taiwan’s Biomedical Industry Innovation Program. In this exclusive interview, he documents his main priorities and the government’s unrivalled commitment to further enhancing the attractiveness of Taiwan’s biotech ecosystem and bolstering a win-win relationship between Taiwan, the…

Switzerland Switzerland has been long-established as one of the world’s most innovative countries and boasts a thriving ecosystem of startup biotechs. However, a slow and complex funding cycle means that an increasing number of Swiss biotechs are looking towards the US for funding; a trend that risks destabilising and weakening the…

Taiwan Chih-Kung Lee, Minister of Economic Affairs of the Republic of China (Taiwan) provides insights into Taiwan’s “new economic model” recently established by the new government to boost the country’s economic growth and ensure Taiwan renews its role as an innovation pioneer. He also documents the crucial role that the pharmaceutical…

Luxembourg Marc Schiltz reveals the ambitions of Luxembourg’s National Research Fund (FNR), how his team are encouraging integration and doing far more than just delivering funds to willing researchers. Over the past 5 years, you have taken it upon yourself to internally reorganize the Luxembourg National Research Fund ( FNR), sharpen…

Switzerland Walter Steinlin describes the Federal Commission of Technology and Innovation as a catalyst for turning research into innovation. Based in Bern, Switzerland, the commission funds research institutes in corporate projects, and provides mentorship and coaching support for start-ups. Could you give our international audience an overview of the Federal Commission…